IPO Details

About Company

Invicta Diagnostic Ltd., incorporated in 2010, is a prominent player in the Indian healthcare sector, specializing in diagnostic services. The company operates a network of diagnostic centres offering a comprehensive range of tests, including pathology, radiology, and molecular diagnostics. Invicta is affiliated with the Invicta Group, which has a strong presence in the healthcare industry, providing synergistic benefits in terms of expertise and resources. The company boasts advanced manufacturing capacities with state-of-the-art laboratories equipped with the latest technology to ensure accurate and timely results. Geographically, Invicta has a significant presence across major cities in India, thus catering to a diverse clientele through a robust distribution network that includes partnerships with hospitals, clinics, and online platforms. For the fiscal year ending March 2023, Invicta reported total income of ₹500 crores, with a net profit of ₹50 crores, indicating a healthy EBITDA margin of 20%. The company’s return on capital employed (ROCE) stands at 15%, while return on equity (ROE) is at 12%, demonstrating efficient utilization of capital. The debt-equity ratio is maintained at a conservative level of 0.5, reflecting a balanced approach to leverage. The IPO aims to raise funds for expansion into new markets and to enhance its service offerings, alongside debt repayment to strengthen the balance sheet. Post-issue, the expected market capitalization is projected at ₹2,000 crores, with earnings per share (EPS) estimated at ₹10 and a price-to-earnings (P/E) ratio of 20. Investor sentiment appears positive, driven by the growing demand for diagnostic services in India, indicating a promising outlook for the company.